TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26241253

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg intramuscular injection
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo saline injection
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg intramuscular injection (Nulliparous participants)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo saline injection (Nulliparous participants)
Number of subjects: 67
Study: 23764734

Group type: EXPERIMENTAL
Intervention: GLP-1 (7-36) treatment in lean humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GLP-1 (7-36) treatment in obese humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GLP-1 (7-36) treatment in lean swine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GLP-1 (7-36) treatment in obese swine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GLP-1 treatment
Number of subjects: 0
Study: 20587585

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump therapy
Number of subjects: 485

Group type: COMPARATOR
Intervention: Multiple daily insulin injections (injection therapy)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 485
Study: 17641003

Group type: EXPERIMENTAL
Intervention: Low serum magnesium levels
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Elevated hsCRP levels
Number of subjects: 488
Study: 15665201

Group type: EXPERIMENTAL
Intervention: MRI scan within 5 days of injury
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual management (control group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MRI scan
Number of subjects: 28
Study: 12532161

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg tid plus hypocaloric diet for the first year and weight maintenance diet in year two
Number of subjects: 220
Study: 10426245

Group type: EXPERIMENTAL
Intervention: Reduced schedule of six to seven antenatal visits
Number of subjects: 1117

Group type: COMPARATOR
Intervention: Traditional schedule of 13 antenatal visits
Number of subjects: 1117
Study: 9454228

Group type: EXPERIMENTAL
Intervention: Cancer of larynx
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Malignant neoplasms of maxillo‐ethmoid complex
Number of subjects: 49

Group type: COMPARATOR
Intervention: Healthy people
Number of subjects: 49
Study: 1698446

Group type: EXPERIMENTAL
Intervention: MC903
Number of subjects: 20

Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MC903 and Betamethasone
Number of subjects: 20
Study: 6449753

Group type: EXPERIMENTAL
Intervention: ipratropium bromide 1 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ipratropium bromide 0.1 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 10
Study: 30077419

Group type: EXPERIMENTAL
Intervention: Intralesional steroid (ILS) injection
Number of subjects: 29

Group type: COMPARATOR
Intervention: Microlaryngeal surgery
Number of subjects: 29
Study: 28832876

Group type: EXPERIMENTAL
Intervention: Cigarettes with 0.4 mg/g nicotine content
Number of subjects: 169

Group type: COMPARATOR
Intervention: Higher nicotine content cigarettes
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: All nicotine doses
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Higher nicotine doses
Number of subjects: 169
Study: 26343274

Group type: EXPERIMENTAL
Intervention: Tight-control treatment strategy using the handscan (TCHS)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Clinical assessments (TC)
Number of subjects: 299
Study: 23582109

Group type: EXPERIMENTAL
Intervention: Self-applied transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Baclofen (10 mg twice daily, increasing to 25 mg over three weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Comparison of TENS vs Baclofen
Number of subjects: 52
Study: 21223623

Group type: EXPERIMENTAL
Intervention: Tele-care intervention (telephone and mail support)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Self-help group (control)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Tele-care intervention
Number of subjects: 118
Study: 19146145

Group type: EXPERIMENTAL
Intervention: SybronEndo gauge
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Maillefer gauge
Number of subjects: 80
Study: 17434899

Group type: EXPERIMENTAL
Intervention: Docetaxel 70 mg/m² on day 2 plus oral estramustine 280 mg twice daily on days 1-5 (DE)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m² on day 1 (D)
Number of subjects: 92
Study: 12927020

Group type: EXPERIMENTAL
Intervention: Ascorbate (1000 mg daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11820041

Group type: EXPERIMENTAL
Intervention: Intensive intravenous insulin therapy (maintenance of blood glucose at a level between 80 and 110 mg/dl)
Number of subjects: 1548

Group type: COMPARATOR
Intervention: Conventional treatment (infusion of insulin only if the blood glucose level exceeded 215 mg/dl and maintenance of glucose at a level between 180 and 200 mg/dl)
Number of subjects: 1548
Study: 9623009

Group type: EXPERIMENTAL
Intervention: Intravenous ranitidine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous famotidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no H2 blockers)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 10
Study: 9174500

Group type: EXPERIMENTAL
Intervention: Health education every 2 months by trained practice nurses for 1 year
Number of subjects: 1337

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1337

Group type: EXPERIMENTAL
Intervention: Health education
Number of subjects: 1337

Group type: EXPERIMENTAL
Intervention: Stage 5 (sustaining desired changes in behavior)
Number of subjects: 1337
Study: 2126746

Group type: EXPERIMENTAL
Intervention: Isoflurane-N2O anesthesia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Opioid-N2O anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normocarbia (control)
Number of subjects: 100
Study: 7023223

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 50

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside and Furosemide
Number of subjects: 50
Study: 31026419

Group type: EXPERIMENTAL
Intervention: Submucosal injection of tramadol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline solution injection (control)
Number of subjects: 60
Study: 28417355

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 52
Study: 26515222

Group type: EXPERIMENTAL
Intervention: Absorbable suture material (polyglycolic acid)
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Non-absorbable suture material (polypropylene)
Number of subjects: 1126
Study: 23887449

Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no Cytoflavin)
Number of subjects: 30
Study: 20807460

Group type: EXPERIMENTAL
Intervention: Red meat from grass-fed animals
Number of subjects: 20

Group type: COMPARATOR
Intervention: Red meat from concentrate-fed animals
Number of subjects: 20
Study: 18537939

Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 17010738

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg/week
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 12705296

Group type: EXPERIMENTAL
Intervention: Immediate placement of titanium dental implants (Im)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Delayed placement of titanium dental implants (De)
Number of subjects: 46
Study: 10944563

Group type: EXPERIMENTAL
Intervention: Racecadotril (1.5 mg/kg orally every eight hours)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 8919720

Group type: EXPERIMENTAL
Intervention: UltramicroELISA method
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional biologic assay in mice
Number of subjects: 100
Study: 1747268

Group type: EXPERIMENTAL
Intervention: Systematic patient education on cough
Number of subjects: 548

Group type: COMPARATOR
Intervention: Control practices (matched control practices)
Number of subjects: 548
Study: 7047173

Group type: EXPERIMENTAL
Intervention: Penbutolol (mean dose 83 +/- 19 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Penbutolol (same dose as above)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31850777

Group type: EXPERIMENTAL
Intervention: Conventional buccal infiltration by metallic aspirating syringe
Number of subjects: 30

Group type: COMPARATOR
Intervention: Buccal infiltration by computer‐controlled local anaesthetic device (Wand STA)
Number of subjects: 30
Study: 28479217

Group type: EXPERIMENTAL
Intervention: DEF+TEST (200mg testosterone enanthate per week)
Number of subjects: 50

Group type: COMPARATOR
Intervention: DEF (no testosterone)
Number of subjects: 50
Study: 27454528

Group type: EXPERIMENTAL
Intervention: PDT (Photodynamic Therapy with curcumin and blue light)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PDT + S (Photodynamic Therapy with curcumin, surfactant SDS, and blue light)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chlorhex (Chlorhexidine treatment)
Number of subjects: 24

Group type: COMPARATOR
Intervention: PDT + S
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chlorhex
Number of subjects: 24
Study: 24852116

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab (gemcitabine 1000 mg/m² and oxaliplatin 100 mg/m² with cetuximab 500 mg/m²)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Chemotherapy alone (gemcitabine 1000 mg/m² and oxaliplatin 100 mg/m²)
Number of subjects: 150
Study: 22995673

Group type: EXPERIMENTAL
Intervention: LI85008F formulation (900 mg/day in three divided doses)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (three identical capsules)
Number of subjects: 50
Study: 18710605

Group type: EXPERIMENTAL
Intervention: Salt substitute (65% sodium chloride, 25% potassium chloride, 10% magnesium sulphate)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Normal salt (100% sodium chloride)
Number of subjects: 608
Study: 17617307

Group type: EXPERIMENTAL
Intervention: DDT of the LAD < or = 600 milliseconds (group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: DDT of the LAD > or = 600 milliseconds (group B)
Number of subjects: 24
Study: 14983420

Group type: EXPERIMENTAL
Intervention: Urethral retro-resistance pressure (URP)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Multichannel urodynamics
Number of subjects: 258
Study: 11607801

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 8
Study: 9699761

Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin and gentamicin
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Intramuscular ceftriaxone
Number of subjects: 179

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 179
Study: 7794701

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg twice daily
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg at bedtime
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study: 2927449

Group type: EXPERIMENTAL
Intervention: Lumpectomy followed by breast irradiation
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Total mastectomy
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Lumpectomy with irradiation
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Lumpectomy without irradiation
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Lumpectomy with radiation and adjuvant chemotherapy
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Lumpectomy (with or without irradiation)
Number of subjects: 1843
Study: 30474693

Group type: EXPERIMENTAL
Intervention: KiRA device
Number of subjects: 60
Study: 27940324

Group type: EXPERIMENTAL
Intervention: Memantine 20mg per day added to risperidone
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 46
Study: 26273138

Group type: EXPERIMENTAL
Intervention: Preoperative dose of 100 mg flurbiprofen axetil and postoperative dose of 2 μg/kg sufentanil and 10 mL placebo by PCA pump
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Preoperative dose of 100 mg flurbiprofen axetil and postoperative dose of 2 μg/kg sufentanil and 100 mg flurbiprofen axetil by PCA pump
Number of subjects: 90

Group type: COMPARATOR
Intervention: 10 mL placebo and postoperative dose of 2 μg/kg sufentanil and 10 mL placebo by PCA pump
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative administration of flurbiprofen axetil
Number of subjects: 90
Study: 23732551

Group type: EXPERIMENTAL
Intervention: MedDiet supplemented with extra-virgin olive oil (EVOO) 1 l/week
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: MedDiet supplemented with mixed nuts 30 g/day
Number of subjects: 285

Group type: COMPARATOR
Intervention: Low-fat control diet
Number of subjects: 285
Study: 21690287

Group type: EXPERIMENTAL
Intervention: Oral oseltamivir
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous zanamivir (infused concurrently with oral oseltamivir)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous zanamivir
Number of subjects: 16
Study: 19643572

Group type: EXPERIMENTAL
Intervention: Duloxetine treatment
Number of subjects: 1727

Group type: EXPERIMENTAL
Intervention: Duloxetine maintenance
Number of subjects: 1727

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1727
Study: 17116006

Group type: EXPERIMENTAL
Intervention: Lipid-lowering drugs (9% of subjects in 2004)
Number of subjects: 8827

Group type: COMPARATOR
Intervention: Population without lipid-lowering drugs
Number of subjects: 8827

Group type: EXPERIMENTAL
Intervention: Population aged 65-74 years
Number of subjects: 8827

Group type: COMPARATOR
Intervention: Population with low educational level, BMI >= 25, or smokers
Number of subjects: 8827

Group type: EXPERIMENTAL
Intervention: Population achieving cholesterol levels below 5.0 mmol L(‐1) in 2004
Number of subjects: 8827
Study: 12592544

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Number of subjects: 264
Study: 10788756

Group type: EXPERIMENTAL
Intervention: Antidepressant drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinician ratings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 0
Study: 9303254

Group type: EXPERIMENTAL
Intervention: Educational Support Group
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Professional Support Group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Regular Treatment Group
Number of subjects: 103
Study: 7798822

Group type: EXPERIMENTAL
Intervention: MDI with home-made spacer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MDI with Nebuhaler
Number of subjects: 20

Group type: COMPARATOR
Intervention: MDI alone
Number of subjects: 20
Study: 3531514

Group type: EXPERIMENTAL
Intervention: +cyanidanol-3
Number of subjects: 26
Study: 31392541

Group type: EXPERIMENTAL
Intervention: NPC‐02 (zinc acetate formulation)
Number of subjects: 57
Study: 29621201

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC) - four cycles of 5 min arm ischemia/5 min reperfusion (n = 19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham procedure (n = 21)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 40
Study: 26789425

Group type: EXPERIMENTAL
Intervention: Zofenopril + Acetyl Salicylic Acid (ASA)
Number of subjects: 693

Group type: COMPARATOR
Intervention: Ramipril + Acetyl Salicylic Acid (ASA)
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Zofenopril
Number of subjects: 693

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 693
Study: 25125068

Group type: EXPERIMENTAL
Intervention: Internet-based PCST program and physiotherapy sessions (PCST + Ex)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Online educational material (educational control)
Number of subjects: 148
Study: 22038842

Group type: EXPERIMENTAL
Intervention: Pocket feedback card and feedback session
Number of subjects: 111

Group type: COMPARATOR
Intervention: Usual reminder to provide feedback
Number of subjects: 111
Study: 20042768

Group type: EXPERIMENTAL
Intervention: GL2000 (postshock analysis and pulse check)
Number of subjects: 136

Group type: COMPARATOR
Intervention: GL2005 (immediate CPR resumption)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 136
Study: 18029476

Group type: EXPERIMENTAL
Intervention: 1.1 g/d eicosapentanoic acid (EPA) + docosahexanoic acid (DHA) for 6 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low-energy diets (2 MJ/d) for 4 weeks followed by 4 weeks weight stabilization
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oleic acid (control) for 6 weeks
Number of subjects: 11
Study: 15664094

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine continuously for 48 hours at 2 mL/hour through the ONQ Pain Relief System
Number of subjects: 52

Group type: COMPARATOR
Intervention: saline continuously for 48 hours at 2 mL/hour through the ONQ Pain Relief System
Number of subjects: 52
Study: 11988438

Group type: EXPERIMENTAL
Intervention: Lead awareness intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 10442843

Group type: EXPERIMENTAL
Intervention: Guideline dissemination to all 32 GPs, and a 5-month programme for improvement
Number of subjects: 3950

Group type: COMPARATOR
Intervention: Control group (simple dissemination)
Number of subjects: 3950
Study: 7607280

Group type: EXPERIMENTAL
Intervention: Recombinant Human Interferon Gamma (rIFN-gamma) administered subcutaneously three times weekly at a dose of 0.05 mg per m2
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Recombinant Human Interferon Gamma (rIFN-gamma)
Number of subjects: 28
Study: 2213948

Group type: EXPERIMENTAL
Intervention: Antibiotics (cefazolin, one dose before procedure and then q 6 h until tube removal)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Tube thoracostomy alone
Number of subjects: 90
Study: 975489

Group type: EXPERIMENTAL
Intervention: ICI 74,917 administered from a pressurized aerosol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31445993

Group type: EXPERIMENTAL
Intervention: Digital Media Use
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study: 28902019

Group type: EXPERIMENTAL
Intervention: Subsurface monopolar radiofrequency (SMRF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Microfocused ultrasound with visualization (MFU‐V)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subsurface monopolar radiofrequency (SMRF) and Microfocused ultrasound with visualization (MFU‐V)
Number of subjects: 20
Study: 26160210

Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting (CAS)
Number of subjects: 1713

Group type: COMPARATOR
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 1713
Study: 22997212

Group type: EXPERIMENTAL
Intervention: Nevirapine for 6 weeks
Number of subjects: 5396

Group type: EXPERIMENTAL
Intervention: Nevirapine for 14 weeks
Number of subjects: 5396

Group type: EXPERIMENTAL
Intervention: Nevirapine plus zidovudine for 14 weeks
Number of subjects: 5396

Group type: EXPERIMENTAL
Intervention: Nevirapine for 28 weeks
Number of subjects: 5396

Group type: EXPERIMENTAL
Intervention: Nevirapine (time-varying covariate)
Number of subjects: 5396
Study: 21495074

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study: 18571624

Group type: EXPERIMENTAL
Intervention: Full cognitive intervention (CI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Coping alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Control alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard instruction (SI)
Number of subjects: 40
Study: 16554455

Group type: EXPERIMENTAL
Intervention: Intranasal ciclesonide (800 microg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12713767

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day
Number of subjects: 827

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 827
Study: 10722136

Group type: EXPERIMENTAL
Intervention: Isoniazid prophylaxis for tuberculosis infection
Number of subjects: 25

Group type: COMPARATOR
Intervention: Before treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: 1 month into treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: At least 1 week after treatment cessation
Number of subjects: 25
Study: 8711910

Group type: EXPERIMENTAL
Intervention: FPL protocol
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: VEP protocol
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: FPL and VEP stereoacuity
Number of subjects: 149
Study: 1444522

Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin K1 (1 mg)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Oral vitamin K1 (1 mg)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both groups (oral and intramuscular)
Number of subjects: 165
Study: 3969861

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (1 cup)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (2 cups)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 17
Study: 30851653

Group type: EXPERIMENTAL
Intervention: Gradual exposure (EXP-G; n = 19)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Variable exposure (EXP-V; n = 21)
Number of subjects: 40
Study: 29428960

Group type: EXPERIMENTAL
Intervention: Curcuma aeruginosa extract (CA-ext) applied twice daily via roll-on applicators
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo lotion applied twice daily via roll-on applicators
Number of subjects: 30
Study: 28848902

Group type: EXPERIMENTAL
Intervention: Goal setting cohort
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 115